Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Brenner Tumor 2Tongue Neoplasms 1Salivary Gland Neoplasms 1Lymphoma 1Carcinoma, Ovarian Epithelial 1

Interventions

Cetuximab 13Cisplatin 8Radiotherapy, Intensity-Modulated 6Sorafenib 3Radiotherapy 3Paclitaxel 3Erlotinib Hydrochloride 3Docetaxel 3Carboplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3Taxes 2Sirolimus 2Radiation 2Fluorouracil 2Everolimus 2Drug Therapy 2temsirolimus 1sargramostim 1saracatinib 1mercaptoundecahydrododecaborate 1ixabepilone 1cediranib 1advexin 1Zinc Oxide 1Vorinostat 1VTX-2337 1Ultrasonography 1Tobacco Use Cessation Devices 1Soybean Proteins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Tongue Neoplasms × VTX-2337 × Clear all
NCT01334177 2015-03-05

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

University of Washington

Phase 1 Completed
13 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡